Literature DB >> 32904392

Hypo- vs. normofractionated radiation therapy in breast cancer: A patterns of care analysis in German speaking countries.

M Mayinger1,2, C Straube1,3,4, D Habermehl1,3,4, M N Duma1,3,4, S E Combs1,3,4.   

Abstract

AIM AND
BACKGROUND: To assess the use of hypofractionated (HG-RT) versus normofractionated radiation therapy (NF-RT) in Breast Cancer in German speaking countries.
MATERIALS AND METHODS: Between July 2017 and August 2017, an email-based survey was sent to all 1408 physicians that are members of the German Society of Radiation Oncology (DEGRO). The survey was completed by 180 physicians including 10 private practice owners and 52 heads of departments. The majority (82.1%) of the participants had >15 years of experience in radiation therapy (RT).
RESULTS: The majority (83.9%) of the heads of the departments agreed on using the normofractionated regimen of RT as standard treatment for breast cancer. Several physicians were skeptical about HF-RT with 6.5% of the heads refusing to use HF-RT. 40.3% of the departments had not seen the new German guidelines suggesting HF-RT as the standard treatment for all patients as positive or merely adopted a neutral position toward the guidelines (33.9%). The main points of criticism were increased side effects, an impaired toxicity profile and insufficient data. Most departments (46.8%) that perform HF-RT do so in an individual based manner.
CONCLUSIONS: HF-RT remains controversial in German speaking countries. Our data shows that NF-RT remains the predominant method of treatment. HF-RT is only used in a defined group of patients as most German physicians agree that particular patients, especially those at higher risk of RT late effects, may benefit from a less intense, extended fractionation schedule.
© 2020 Published by Elsevier B.V. on behalf of Greater Poland Cancer Centre.

Entities:  

Keywords:  Breast cancer; DEGRO, German Society of Radiation Oncology; Gy, gray; HF-RT, hypofractionated radiotherapy; Hypofractionated radiotherapy; IORT, intraoperative radiation therapy; Normofractionated radiotherapy; Patterns of care; RT, radiation therapy; SIB, simultaneous integrated boost; SOP, standard operating procedure

Year:  2020        PMID: 32904392      PMCID: PMC7453120          DOI: 10.1016/j.rpor.2020.07.003

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  22 in total

Review 1.  Hypofractionation should be the new 'standard' for radiation therapy after breast conserving surgery.

Authors:  Caroline L Holloway; Valerie Panet-Raymond; Ivo Olivotto
Journal:  Breast       Date:  2010-06       Impact factor: 4.380

2.  Hypofractionated radiotherapy for breast cancer patients treated by breast-conserving surgery: short-term morbidity and preliminary results.

Authors:  Georgios A Plataniotis; Maria-Aikaterini Theofanopoulou; Konstantinia Sotiriadou; Georgios Kyrgias
Journal:  Breast Cancer       Date:  2009-04-07       Impact factor: 4.239

3.  Understanding variations in the use of hypofractionated radiotherapy and its specific indications for breast cancer: A mixed-methods study.

Authors:  Joan Prades; Manel Algara; Josep A Espinàs; Blanca Farrús; Meritxell Arenas; Victoria Reyes; Virginia García-Reglero; Maria Josep Cambra; Esther Rubio; Lluis Anglada; Arantxa Eraso; Agustí Pedro; Maria J Fuentes-Raspall; Victòria Tuset; Judit Solà; Josep M Borras
Journal:  Radiother Oncol       Date:  2017-02-21       Impact factor: 6.280

4.  Hypofractionated radiotherapy in the treatment of early breast cancer.

Authors:  George Plataniotis
Journal:  World J Radiol       Date:  2010-06-28

5.  Recent Trends in Breast Cancer Incidence and Mortality in Germany.

Authors:  Alexander Katalinic; Ron Pritzkuleit; Annika Waldmann
Journal:  Breast Care (Basel)       Date:  2009-04-24       Impact factor: 2.860

6.  Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

Authors:  M Overgaard; P S Hansen; J Overgaard; C Rose; M Andersson; F Bach; M Kjaer; C C Gadeberg; H T Mouridsen; M B Jensen; K Zedeler
Journal:  N Engl J Med       Date:  1997-10-02       Impact factor: 91.245

7.  The effects of dose-fractionation on radiation-induced heart disease in rats.

Authors:  S Lauk; S Rüth; K R Trott
Journal:  Radiother Oncol       Date:  1987-04       Impact factor: 6.280

Review 8.  Effects of age on the detection and management of breast cancer.

Authors:  Andrew McGuire; James A L Brown; Carmel Malone; Ray McLaughlin; Michael J Kerin
Journal:  Cancers (Basel)       Date:  2015-05-22       Impact factor: 6.639

Review 9.  Hypofractionated whole breast irradiation: new standard in early breast cancer after breast-conserving surgery.

Authors:  Kyung Su Kim; Kyung Hwan Shin; Noorie Choi; Sea-Won Lee
Journal:  Radiat Oncol J       Date:  2016-06-17

10.  The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.

Authors:  S M Bentzen; R K Agrawal; E G A Aird; J M Barrett; P J Barrett-Lee; S M Bentzen; J M Bliss; J Brown; J A Dewar; H J Dobbs; J S Haviland; P J Hoskin; P Hopwood; P A Lawton; B J Magee; J Mills; D A L Morgan; J R Owen; S Simmons; G Sumo; M A Sydenham; K Venables; J R Yarnold
Journal:  Lancet       Date:  2008-03-19       Impact factor: 79.321

View more
  2 in total

Review 1.  Preoperative hypofractionated radiotherapy for soft tissue sarcomas: a systematic review.

Authors:  Siyer Roohani; Felix Ehret; Marta Kobus; Anne Flörcken; Sven Märdian; Jana Käthe Striefler; Daniel Rau; Robert Öllinger; Armin Jarosch; Volker Budach; David Kaul
Journal:  Radiat Oncol       Date:  2022-09-14       Impact factor: 4.309

2.  Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial.

Authors:  David Krug; Reinhard Vonthein; Andreas Schreiber; Alexander D Boicev; Jörg Zimmer; Reinhold Laubach; Nicola Weidner; Stefan Dinges; Matthias Hipp; Ralf Schneider; Evelyn Weinstrauch; Thomas Martin; Juliane Hörner-Rieber; Denise Olbrich; Alicia Illen; Nicole Heßler; Inke R König; Kathrin Dellas; Jürgen Dunst
Journal:  Strahlenther Onkol       Date:  2020-12-15       Impact factor: 3.621

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.